Amarin (NASDAQ:AMRN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Amarin (NASDAQ:AMRN) in a research note released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Amarin Stock Performance

NASDAQ AMRN opened at $9.11 on Wednesday. Amarin has a 52-week low of $7.08 and a 52-week high of $20.60. The business has a 50 day simple moving average of $9.78 and a 200 day simple moving average of $10.44. The stock has a market cap of $187.06 million, a price-to-earnings ratio of -101.22 and a beta of 1.38.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($1.20) by ($1.20). The company had revenue of $62.31 million during the quarter, compared to the consensus estimate of $32.37 million. Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. On average, analysts predict that Amarin will post -0.15 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Arkfeld Wealth Strategies L.L.C. boosted its position in Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 20,000 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in Amarin in the 4th quarter valued at about $36,000. Generation Capital Management LLC acquired a new stake in Amarin during the fourth quarter worth approximately $50,000. Stonepine Capital Management LLC bought a new stake in shares of Amarin during the fourth quarter worth approximately $55,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Amarin in the fourth quarter valued at approximately $68,000. 22.25% of the stock is owned by institutional investors and hedge funds.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.